Nuo Therapeutics, Inc., (Nuo Therapeutics) formerly Cytomedix, Inc. is a biomedical company. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. The Company pioneers biodynamic therapies within the emerging opportunities of a changing healthcare landscape. Nuo Therapeutics' flagship product, Aurix, is a biodynamic hematogel that uses a patient's own platelets and plasma as a catalyst for healing. It is the only therapy that is FDA-cleared for use on ulcers and wounds of all types. Its commercial offerings consist of point of care technologies for the safe and efficient separation of autologous blood and bone marrow to produce platelet based therapies or cell concentrates. It has two distinct platelet rich plasma (PRP) devices, the AutoloGel TM System (relaunched as Aurix in October 2014) for wound care and the Angel concentrated Platelet Rich Plasma (cPRP) System for orthopedics markets.